MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Status:
Recruiting
Trial end date:
2027-06-15
Target enrollment:
Participant gender:
Summary
Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma
(EMZL). It is planned to recruit 130 patients.
Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal
Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore
the clinical activity and safety of the combination treatment proposed.
The study primary endpoints will be analysed on the EMZL population. Outcome of patients with
SMZL and NMZL will be analysed and reported separately
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)